COMPARISON OF CHOLESTEROL PLASMA CONCENTRATION AND PROCALCITONIN LEVEL AS PREDICTOR WORSENING OF SEPSIS

Fathur Rahman, Yutu Solihat, Achsanuddin Hanafie

Abstract


ICU patients with infection and MODS, measurements of PCT, CRP and cholesterol were measured on day 1, 5 and
the last day of ICU admission. PCT and cholesterol values have high sensitivity and speci􀃶city in septic patients with
MODS This study aims to determine the comparison of cholesterol levels and procalcitonin levels as predictors of mortality in septic
patients. The research method used is analytic observational. The study was conducted at the General Hospital of the Department of
Anesthesiology and Intensive Therapy of the Faculty of Medicine, University of North Sumatra from June to August 2018. The total samples
obtained were 46 sepsis patients. The diagnosis of sepsis is based on the QSOFA criteria assessed when sepsis is established (T0), at 3 days
after sepsis (T1), at 5 days after sepsis. From the results obtained showed that there were 46 patients consisting of 30 people (65.3%) and 16
women (34.7%). The average age of patients in this study was 42.39 years the results of the analysis found that a signi􀃶cant relationship
between procalcitonin and cholesterol with worsening in sepsis at sepsis was established (T0), at 3 days after sepsis (T1), at 5 days after
sepsis (T2) using Pearson correlation (p < 0.05). From the results of the analysis using the ROC curve at T0, T1, and T2 it was found that the
area under the ROC curve (AUC) with the percentage of 44.7%, 40.3% and 44.1% respectively (95% CI 26.6% - 62.8%, p = 0.556). In addition, it
was also found that there was no correlation between the results of cholesterol levels as a predictor of worsening in septic patients (t<4,06).
The diagnostic value of cholesterol levels does not have a good ability to predict worsening in sepsis patients (p> 0.05), whereas
procalcitonin can be a gold standard in establishing sepsis but does not have a good relationship as a predictor of worsening in sepsis


Keywords


Cholesterol, Procalcitonin, Sepsis, SOFA scores

Full Text:

PDF

References


Nasronudin. Imunopatogenesis Sepsis and Management Principles. In: Infection Diseases in Indonesia. Surabaya: Airlangga University Press; 2007. p. 238–45.

Martin G, Mannino D. The epidemiology of sepsis in the United States from 1979 through 2000. New Engl J Med. 2003;1546–54.

Müller-Redetzky H, Suttorp N, Witzenrath M. Experimental models of pneumonia-induced sepsis. Drug Discov Today Dis Model. 2012 Mar;9(1):e23–32.

Engel C, Brunkhorst FM, Bone H-G, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007 Apr;33(4):606–18.

Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, et al. Procalcitonin as an early indicator of outcome in sepsis : a prospective observational study. J Hosp Infect. 2011 Jan;77(1):58–63.

Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010 Jan 1;159(2):253–64.

Kopterides P., Tsangaris I. Procalcitonin and sepsis : recent data on diagnostic utility , prognostic potential and therapeutic implications in critically ill patients. Minerva Anestesiol. 2012;1–26.

Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002 Sep;323(1-2):17–29.

Ugarte H., Silva E., Mercan D., Mendonca A. D. Vincent JL. Procalcitonin used as marker of infection in the intensive care unit. Crit Care Med. 1999;27(2):498–504.

Tang BMP, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007 Mar;7(3):210–7.

Murzalina C. Procalcitonin in the sepsis patient in ICU. USU Press. Universitas Sumatera Utara; 2007.

Buchori P. Diagnose Sepsis Used Procalcitonin. Indones J Clin Pathol Med Lab. 2006;12:131–7.

Signs C. Diagnosis of Pneumonia in Adults in General Practice. Scand J Prim Heal Care. 1992;10(May 1989):226–33.

Melbye H., Straumer B., Aasebo U., Broxa J. The Diagnosis of Adult Pneumonia in General Practice. Scand J Prim Heal Care. 1988;6:111–7.

Hammer C, Hobel G, Hamme S, et al. Diagnosis and Monitoring of Inflammatory Events in Transplant Patients. In: Trull Ak, Demers LM, Holt DW, et. al., editor. Biomarkers of Disease An Evidence-Based Approach. Cambridge United Kingdom: Cambridge University Press; 2002. p. 474–88.

Guntur H. A. SIRS, Sepsis and Septic Shock. Surakarta: Sebelas Maret University Press; 2008. 1-14 p.

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Jun;31(4):1250–6.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Surviv Sepsis Campaign. 2012;

Brunkhorst F, Wegscheider K. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 2000;26:148–53.

Harbarth S, Holeckova K, Pittet D, Ricou B, Grau GE, Vadas L. Diagnostic Value of Procalcitonin, Interleukin-6 and Interleukin-8 in Critically III Patients Admitted with Suspected Sepsis. Am J Respir Crit Care Med. 2001;164:396–402.

Dorizzi RM, Polati E, Sette P, Ferrari A, Rizzotti P, Luzzani A. Procalcitonin in the diagnosis of inflammation in intensive care units. Clin Biochem. 2006 Dec;39(12):1138–43.

Giamarellos-bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, et al. Procalcitonin as an early indicator of outcome in sepsis : a prospective observational study. 2011;77:58–63.

Rau B, Krüger C, Schilling M. Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbeck’s Arch Surg. 2004;134–44.

Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med. 2000 Sep;26(9):1193–200.

Abu Elkhashab AE, Swelem RS, Abd Alla AED a., Hattata E a., Atta MS. Etiological and prognostic values of procalcitonin in hospital-acquired pneumonia. Egypt J Chest Dis Tuberc. The Egyptian Society of Chest Diseases and Tuberculosis; 2014 Jan;63(1):201–6.

BalcI C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanogu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care. 2003;3:85–90.

Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care. 2004 Aug;8(4):R234–42.

Jeong S, Park Y, Cho Y, Kim H-S. Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture. Clin Chim Acta. Elsevier B.V.; 2012 Nov 12;413(21-22):1731–6.

Köszegi T. Immunoluminometric detection of human procalcitonin. J Biochem Biophys Methods. 2002;53(1-3):157–64.


Refbacks

  • There are currently no refbacks.